TY - JOUR T1 - Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality JF - medRxiv DO - 10.1101/2020.12.16.20248294 SP - 2020.12.16.20248294 AU - William Morgenlander AU - Stephanie Henson AU - Daniel Monaco AU - Athena Chen AU - Kirsten Littlefield AU - Evan M. Bloch AU - Eric Fujimura AU - Ingo Ruczinski AU - Andrew R. Crowley AU - Harini Natarajan AU - Savannah E. Butler AU - Joshua A. Weiner AU - Mamie Z. Li AU - Tania S. Bonny AU - Sarah E. Benner AU - Ashwin Balagopal AU - David Sullivan AU - Shmuel Shoham AU - Thomas C. Quinn AU - Susan Eshleman AU - Arturo Casadevall AU - Andrew D. Redd AU - Oliver Laeyendecker AU - Margaret E. Ackerman AU - Andrew Pekosz AU - Stephen J. Elledge AU - Matthew Robinson AU - Aaron A.R. Tobian AU - H. Benjamin Larman Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248294.abstract N2 - COVID-19 convalescent plasma, particularly plasma with high-titer SARS-CoV-2 (CoV2) antibodies, has been successfully used for treatment of COVID-19. The functionality of convalescent plasma varies greatly, but the association of antibody epitope specificities with plasma functionality remains uncharacterized. We assessed antibody functionality and reactivities to peptides across the CoV2 and the four endemic human coronavirus (HCoV) genomes in 126 COVID-19 convalescent plasma donations. We found strong correlation between plasma functionality and polyclonal antibody targeting of CoV2 spike protein peptides. Antibody reactivity to many HCoV spike peptides also displayed strong correlation with plasma functionality, including pan-coronavirus cross-reactive epitopes located in a conserved region of the fusion peptide. After accounting for antibody cross-reactivity, we identified an association between greater alphacoronavirus NL63 antibody responses and development of highly neutralizing antibodies to SARS-CoV-2. We also found that plasma preferentially reactive to the CoV2 receptor binding domain (RBD), versus the betacoronavirus HKU1 RBD, had higher neutralizing titer. Finally, we developed a two-peptide serosignature that identifies plasma donations with high anti-S titer but that suffer from low neutralizing activity. These results suggest that analysis of coronavirus antibody fine specificities may be useful for selecting therapeutic plasma with desired functionalities.Competing Interest StatementH.B.L. and S.J.E. are inventors on a patent application (US20160320406A) filed by Brigham and Women's Hospital that covers the use of the VirScan technology to identify pathogen antibodies and are founders of ImmuneID. H.B.L. is a founder of Alchemab and is an advisor to CDI Laboratories and TSCAN Therapeutics. S.J.E. is a founder of TSCAN Therapeutics, MAZE Therapeutics and Mirimus. S.J.E. serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics, MAZE, XChem, and is an advisor for MPM. S.S. has received grants from Ansun, Astrellas, Cidara, F2G, Merck, T2, Reviral, Shire, Shionogi, and Scynexis. S.S has received personal fees from Acidophil, Amplyx, Janssen, Merck, Reviral, Karyopharm, Intermountain Health, and Immunome.Funding StatementThis study was made possible by grants from: the Johns Hopkins COVID-19 Research Response Program, National Institute of General Medical Sciences (NIGMS) grant R01GM136724 and a National Institute of Allergy and Infectious Diseases (NIAID) grant U24AI118633 (H.B.L.); NIAID R01AI120938, R01AI120938S1 and R01AI128779 (A.A.R.T); NIH grants AI052733, AI15207 and HL059842 (A.C.); in part by the Division of Intramural Research, NIAID, NIH (O.L., A.R., T.Q.); National Heart Lung and Blood Institute 1K23HL151826-01 (E.M.B); Bloomberg Philanthropies (A.C.); Department of Defense W911QY2090012 (D.S.); NIH Center of Excellence for Influenza Research and Surveillance grant HHSN272201400007C (A.P.); the MassCPR and VOVRN (S.J.E); and HIV Prevention Trials Network grant UM1AI068613 (S.E.) We are grateful to the National Institute of Infectious Diseases, Japan, for providing VeroE6TMPRSS2 cells and acknowledge the Centers for Disease Control and Prevention, BEI Resources, NIAID, NIH for providing SARS-related coronavirus 2, isolate USA-WA1/2020, NR-5228.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written consent was received from all study participants. The Johns Hopkins University School of Medicine Institutional Review Board reviewed and approved the sample collection and this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request from the corresponding author. ER -